Comments
Loading...

Amedisys Analyst Ratings

AMEDNASDAQ
Logo brought to you by Benzinga Data
$91.44
-0.07-0.08%
At close: -
$91.44
0.000.00%
After Hours: 4:00 PM EDT
Consensus Rating1
Outperform
Highest Price Target1
$182.00
Lowest Price Target1
$85.00
Consensus Price Target1
$111.48

Amedisys Analyst Ratings and Price Targets | NASDAQ:AMED | Benzinga

Amedisys Inc has a consensus price target of $111.48 based on the ratings of 24 analysts. The high is $182 issued by Credit Suisse on April 29, 2022. The low is $85 issued by SVB Leerink on January 5, 2023. The 3 most-recent analyst ratings were released by Stephens & Co., Stephens & Co., and Deutsche Bank on March 4, 2025, February 12, 2025, and July 31, 2024, respectively. With an average price target of $101 between Stephens & Co., Stephens & Co., and Deutsche Bank, there's an implied 10.45% upside for Amedisys Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Feb
1
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
2.5
Sell
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Stephens & Co.
Stephens & Co.
Deutsche Bank
Cantor Fitzgerald
RBC Capital

1calculated from analyst ratings

Analyst Ratings for Amedisys

Buy NowGet Alert
03/04/2025Buy Now10.45%Stephens & Co.
Scott Fidel 42%
$101 → $101ReiteratesEqual-Weight → Equal-WeightGet Alert
02/12/2025Buy Now10.45%Stephens & Co.
Raj Kumar 45%
$101 → $101ReiteratesEqual-Weight → Equal-WeightGet Alert
07/31/2024Buy Now10.45%Deutsche Bank
Justin Bowers49%
$101 → $101DowngradeBuy → HoldGet Alert
07/25/2024Buy Now10.45%Cantor Fitzgerald
Sarah James53%
$101 → $101ReiteratesNeutral → NeutralGet Alert
07/01/2024Buy Now—William Blair
Matt Larew20%
—DowngradeOutperform → Market PerformGet Alert
04/25/2024Buy Now10.45%Cantor Fitzgerald
Sarah James53%
$101 → $101ReiteratesNeutral → NeutralGet Alert
03/26/2024Buy Now—Raymond James
John Ransom76%
—MaintainsMarket PerformGet Alert
03/25/2024Buy Now9.36%RBC Capital
Ben Hendrix61%
$97 → $100MaintainsOutperformGet Alert
09/14/2023Buy Now10.45%Cantor Fitzgerald
Sarah James53%
$100 → $101MaintainsNeutralGet Alert
07/31/2023Buy Now10.45%TD Cowen
Gary Taylor63%
$84 → $101MaintainsMarket PerformGet Alert
07/27/2023Buy Now10.45%Credit Suisse
Jonathan Yong66%
→ $101ReiteratesNeutral → NeutralGet Alert
07/06/2023Buy Now10.45%Jefferies
Brian Tanquilut45%
$98 → $101DowngradeBuy → HoldGet Alert
06/28/2023Buy Now—Benchmark
Bill Sutherland64%
—DowngradeBuy → HoldGet Alert
06/27/2023Buy Now—Benchmark
Bill Sutherland64%
—DowngradeBuy → HoldGet Alert
06/27/2023Buy Now10.45%Truist Securities
David Macdonald68%
$97 → $101MaintainsHoldGet Alert
06/07/2023Buy Now6.08%Truist Securities
David Macdonald68%
→ $97DowngradeBuy → HoldGet Alert
06/06/2023Buy Now9.36%Cantor Fitzgerald
Sarah James53%
$91 → $100MaintainsNeutralGet Alert
06/06/2023Buy Now25.77%Benchmark
Bill Sutherland64%
→ $115ReiteratesBuy → BuyGet Alert
06/06/2023Buy Now9.36%Credit Suisse
Jonathan Yong66%
$115 → $100DowngradeOutperform → NeutralGet Alert
05/08/2023Buy Now-8.14%TD Cowen
Gary Taylor63%
$95 → $84MaintainsMarket PerformGet Alert
05/05/2023Buy Now-3.76%Barclays
Steve Valiquette55%
$93 → $88MaintainsEqual-WeightGet Alert
05/04/2023Buy Now6.08%Truist Securities
David Macdonald68%
$115 → $97MaintainsBuyGet Alert
05/04/2023Buy Now12.64%Stephens & Co.
Scott Fidel71%
→ $103Reiterates → Equal-WeightGet Alert
04/21/2023Buy Now-4.86%Cantor Fitzgerald
Sarah James53%
→ $87Initiates → NeutralGet Alert
04/13/2023Buy Now25.77%Truist Securities
David Macdonald68%
$130 → $115MaintainsBuyGet Alert
03/14/2023Buy Now25.77%Benchmark
Bill Sutherland64%
→ $115Reiterates → BuyGet Alert
03/14/2023Buy Now12.64%Stephens & Co.
Scott Fidel71%
→ $103Reiterates → Equal-WeightGet Alert
03/13/2023Buy Now1.71%Barclays
Steve Valiquette55%
→ $93Initiates → Equal-WeightGet Alert
02/27/2023Buy Now25.77%Credit Suisse
Jonathan Yong66%
→ $115Reiterates → OutperformGet Alert
02/21/2023Buy Now21.39%RBC Capital
Ben Hendrix61%
$114 → $111MaintainsOutperformGet Alert
02/16/2023Buy Now3.89%Stephens & Co.
Scott Fidel71%
→ $95Reiterates → Equal-WeightGet Alert
02/16/2023Buy Now25.77%Benchmark
Mark Miller65%
$120 → $115MaintainsBuyGet Alert
02/13/2023Buy Now31.23%Benchmark
Bill Sutherland64%
→ $120Reiterates → BuyGet Alert
01/25/2023Buy Now31.23%Benchmark
Bill Sutherland64%
$135 → $120MaintainsBuyGet Alert
01/23/2023Buy Now25.77%Credit Suisse
Jonathan Yong66%
$140 → $115MaintainsOutperformGet Alert
01/19/2023Buy Now36.7%Oppenheimer
Colin Rusch53%
$145 → $125MaintainsOutperformGet Alert
01/05/2023Buy Now-7.04%SVB Leerink
Whit Mayo67%
$96 → $85MaintainsMarket PerformGet Alert
11/11/2022Buy Now15.92%Stephens & Co.
Scott Fidel71%
$122 → $106MaintainsEqual-WeightGet Alert
11/01/2022Buy Now4.99%SVB Leerink
Whit Mayo67%
$116 → $96MaintainsMarket PerformGet Alert
11/01/2022Buy Now33.42%Stephens & Co.
Scott Fidel71%
$105 → $122MaintainsEqual-WeightGet Alert
10/31/2022Buy Now52.01%RBC Capital
Frank Morgan46%
$165 → $139MaintainsOutperformGet Alert
10/28/2022Buy Now37.8%Barclays
Sarah James53%
$154 → $126MaintainsOverweightGet Alert
10/28/2022Buy Now14.83%Stephens & Co.
Scott Fidel71%
$120 → $105MaintainsEqual-WeightGet Alert
10/28/2022Buy Now42.17%Truist Securities
David Macdonald68%
$140 → $130MaintainsBuyGet Alert
10/28/2022Buy Now58.57%Oppenheimer
Michael Wiederhorn63%
$175 → $145MaintainsOutperformGet Alert
10/27/2022Buy Now—Raymond James
John Ransom76%
—DowngradeOutperform → Market PerformGet Alert
10/24/2022Buy Now80.45%Deutsche Bank
Justin Bowers49%
$175 → $165MaintainsBuyGet Alert
10/05/2022Buy Now53.11%Truist Securities
David Macdonald68%
$150 → $140MaintainsBuyGet Alert
10/03/2022Buy Now47.64%Benchmark
Bill Sutherland64%
$165 → $135MaintainsBuyGet Alert
08/02/2022Buy Now3.89%UBS
Andrew Mok58%
$145 → $95DowngradeNeutral → SellGet Alert
08/01/2022Buy Now53.11%Raymond James
John Ransom76%
$180 → $140MaintainsOutperformGet Alert
07/29/2022Buy Now68.42%Barclays
Sarah James53%
$181 → $154MaintainsOverweightGet Alert
07/28/2022Buy Now80.45%Benchmark
Bill Sutherland64%
$175 → $165MaintainsBuyGet Alert
07/14/2022Buy Now64.04%Truist Securities
David Macdonald68%
$175 → $150MaintainsBuyGet Alert
06/29/2022Buy Now39.98%Stifel
Tao Qiu44%
→ $128Initiates → HoldGet Alert
06/21/2022Buy Now11.55%B of A Securities
Joanna Gajuk66%
$145 → $102DowngradeNeutral → UnderperformGet Alert
06/21/2022Buy Now91.38%Deutsche Bank
Justin Bowers49%
$210 → $175MaintainsBuyGet Alert
06/21/2022Buy Now91.38%Truist Securities
David Macdonald68%
$200 → $175MaintainsBuyGet Alert
06/21/2022Buy Now36.7%Stephens & Co.
Scott Fidel71%
$155 → $125MaintainsEqual-WeightGet Alert
06/21/2022Buy Now17.02%SVB Leerink
Whit Mayo67%
$117 → $107MaintainsMarket PerformGet Alert
05/27/2022Buy Now27.95%SVB Leerink
Whit Mayo67%
$131 → $117MaintainsMarket PerformGet Alert
04/29/2022Buy Now99.04%Credit Suisse
A.J. Rice70%
$181 → $182MaintainsOutperformGet Alert
04/29/2022Buy Now96.85%Raymond James
John Ransom76%
$200 → $180MaintainsOutperformGet Alert
04/29/2022Buy Now43.26%SVB Leerink
Whit Mayo67%
$162 → $131MaintainsMarket PerformGet Alert

FAQ

Q

What is the target price for Amedisys (AMED) stock?

A

The latest price target for Amedisys (NASDAQ:AMED) was reported by Stephens & Co. on March 4, 2025. The analyst firm set a price target for $101.00 expecting AMED to rise to within 12 months (a possible 10.45% upside). 6 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Amedisys (AMED)?

A

The latest analyst rating for Amedisys (NASDAQ:AMED) was provided by Stephens & Co., and Amedisys reiterated their equal-weight rating.

Q

When was the last upgrade for Amedisys (AMED)?

A

There is no last upgrade for Amedisys

Q

When was the last downgrade for Amedisys (AMED)?

A

The last downgrade for Amedisys Inc happened on July 31, 2024 when Deutsche Bank changed their price target from $101 to $101 for Amedisys Inc.

Q

When is the next analyst rating going to be posted or updated for Amedisys (AMED)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amedisys, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amedisys was filed on March 4, 2025 so you should expect the next rating to be made available sometime around March 4, 2026.

Q

Is the Analyst Rating Amedisys (AMED) correct?

A

While ratings are subjective and will change, the latest Amedisys (AMED) rating was a reiterated with a price target of $101.00 to $101.00. The current price Amedisys (AMED) is trading at is $91.44, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch